PAVLOVÁ, Šárka, Jana ŠMARDOVÁ, Nikola TOM and Martin TRBUŠEK. Detection and functional analysis of TP53 mutations in CLL. In Methods in Molecular Biology - Chronic Lymphocytic Leukemia: Methods and Protocols. Humana New York, NY: Springer Science + Business Media, LLC part of Springer Nature, 2019, p. 63-81, 20 pp. 1881. ISBN 978-1-4939-9405-2. Available from: https://dx.doi.org/10.1007/978-1-4939-8876-1.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Detection and functional analysis of TP53 mutations in CLL
Authors PAVLOVÁ, Šárka, Jana ŠMARDOVÁ, Nikola TOM and Martin TRBUŠEK.
Edition Humana New York, NY, Methods in Molecular Biology - Chronic Lymphocytic Leukemia: Methods and Protocols, p. 63-81, 20 pp. 1881, 2019.
Publisher Springer Science + Business Media, LLC part of Springer Nature
Other information
Original language English
Type of outcome Chapter(s) of a specialized book
Field of Study 10608 Biochemistry and molecular biology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Publication form printed version "print"
WWW URL
Organization unit Central European Institute of Technology
ISBN 978-1-4939-9405-2
Doi http://dx.doi.org/10.1007/978-1-4939-8876-1
UT WoS 000683074300007
Keywords in English Chronic lymphocytic leukemia; TP53 gene; mutations; next generation sequencing
Tags topvydavatel
Tags International impact, Reviewed
Changed by Changed by: Mgr. Eva Dubská, učo 77638. Changed: 2/5/2024 11:51.
Abstract
Chronic lymphocytic leukemia (CLL) represents a prototype disease in which TP53 gene defects lead to inferior prognosis. Here, we present two distinct methodologies which can be used to identify TP53 mutations in CLL patients; both protocols are primarily intended for research purposes. The functional analysis of separated alleles in yeast (FASAY) can be flexibly adapted to a variable number of samples and provides an immediate functional readout of identified mutations. Amplicon-based next-generation sequencing then allows for a high throughput and accurately detects subclonal TP53 variants.
Links
LM2015091, research and development projectName: Národní centrum lékařské genomiky (Acronym: NCLG)
Investor: Ministry of Education, Youth and Sports of the CR
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
TE02000058, research and development projectName: Centrum kompetence pro molekulární diagnostiku a personalizovanou medicínu (Acronym: MOLDIMED)
Investor: Technology Agency of the Czech Republic
15-33999A, interní kód MU
(CEP code: NV15-33999A)
Name: Vývoj nových nízkomolekulárních protinádorových léčiv na principu syntetické letality
Investor: Ministry of Health of the CR
PrintDisplayed: 22/7/2024 00:17